Cargando…
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
BACKGROUND: Hypertension and type 2 diabetes are common co-morbidities. Preliminary studies suggest that thiazolidinediones reduce blood pressure (BP). We therefore used ambulatory BP to quantify BP lowering at 6–12 months with rosiglitazone used in combination with metformin or sulfonylureas compar...
Autores principales: | Komajda, Michel, Curtis, Paula, Hanefeld, Markolf, Beck-Nielsen, Henning, Pocock, Stuart J, Zambanini, Andrew, Jones, Nigel P, Gomis, Ramon, Home, Philip D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2390513/ https://www.ncbi.nlm.nih.gov/pubmed/18435852 http://dx.doi.org/10.1186/1475-2840-7-10 |
Ejemplares similares
-
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
por: Komajda, Michel, et al.
Publicado: (2010) -
Rosiglitazone RECORD study: glucose control outcomes at 18 months
por: Home, P D, et al.
Publicado: (2007) -
Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
por: MacDonald, Michael R., et al.
Publicado: (2011) -
Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012) -
Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017)